Bright Green Corp (BGXXQ) AI Stock Analysis

• Market Cap: $191.17K
• Dividend Yield: N/A
• Average Volume (3M): 156.71K
• Price to Earnings (P/E): ―
• Beta (1Y): -14.27
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 8
• Sector: Technology
• Sector Strength: 88
• Industry: Pharmaceuticals
• EPS (TTM): -0.05
• Shares Outstanding: 191,166,320
• 10 Day Avg. Volume: 218,633
• 30 Day Avg. Volume: 156,711
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 31 Underperform
• Price Target: ―

Bright Green Corp.'s overall stock score reflects substantial financial instability, poor profitability, and challenging valuation metrics. The company's negative cash flow and income statement issues are significant concerns, exacerbated by bearish technical indicators. Despite a low debt position, the lack of profitability and operational efficiency is critical for potential investors.

Bright Green Corp Business Overview & Revenue Model

Company Description

Bright Green Corp. (BGXX) is a company involved in the production and research of cannabis and cannabis-related products. The company operates within the pharmaceutical and biotechnology sectors, focusing on the development and commercialization of federally compliant cannabis products for medical and research purposes. Bright Green Corp. aims to provide innovative solutions for the healthcare and wellness industries through its cultivation and research initiatives.

How the Company Makes Money

Bright Green Corp. makes money primarily through the cultivation and sale of cannabis products intended for medical and research use. The company's revenue model is centered around producing high-quality, federally compliant cannabis that can be used in pharmaceutical applications and scientific research. Key revenue streams include sales agreements with pharmaceutical companies, research institutions, and potentially government contracts for supplying cannabis for approved studies. Strategic partnerships with organizations in the healthcare sector may also contribute to its earnings by facilitating the distribution and utilization of its products in various applications. The company's focus on compliance with federal regulations enables it to operate within a niche market with significant growth potential.

Bright Green Corp Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Bright Green Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BGXXQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.61 is Neutral, neither overbought nor oversold. The STOCH value of 33.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BGXXQ.

Bright Green Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
BMR	―	$44.38M	-9.70	-22.65%	―	5.96%	-156.04%
ASTI	―	$7.17M	-0.44	-181.54%	―	-84.54%	98.57%
OBLG	―	$9.30M	-0.22	-39.27%	―	-22.86%	33.12%
BGXXQ	―	$191.17K	―	―	―	―	―

Bright Green Corp Corporate Events

Bright Green Corp. Restructures Leadership and Strategic Focus

Bright Green Corporation announced a significant leadership restructuring, with key resignations including the CEO and CFO, to facilitate a new strategic direction under the leadership of founder Lynn Stockwell. This restructuring involves a comprehensive realignment of the company’s contracts and operations, positioning it to become a major supplier of plant-based controlled substances to U.S. drug manufacturers. The company plans a reverse stock split and aims for re-listing on a major exchange, while also exploring a franchise model for new agricultural facilities, integrating the USCIS EB-5 program to support domestic job creation and investment in high-elevation greenhouse facilities.